ImmunityBio (IBRX) Receivables - Other (2015 - 2026)
ImmunityBio (IBRX) posted quarterly Receivables - Other of $3000.0 for Q1 2026, down 95.45% year-over-year from $66000.0 in Q1 2025, and down 93.48% quarter-over-quarter from $46000.0 in Q4 2025.
Powered by 
Analysis
ImmunityBio (IBRX) Receivables - Other (2015 - 2026) Analysis & Trends
ImmunityBio (IBRX) has reported Receivables - Other for 12 consecutive years, with $3000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Receivables - Other fell 95.45% year-over-year to $3000.0; the TTM figure through Mar 2026 stood at $3000.0 (down 95.45% YoY), while the FY2025 annual figure was $46000.0, down 77.0% from the prior year.
- Receivables - Other eased to $3000.0 in Q1 2026 per IBRX's latest filing, from $46000.0 in the prior quarter.
- Across five years, Receivables - Other topped out at $5.0 million in Q2 2022 and bottomed at $3000.0 in Q1 2026.
- Historically, Receivables - Other has averaged $1.7 million across 5 years, with a median of $1.7 million in 2025.
- Annual changes were most pronounced in 2022 — Receivables - Other surged 283.44% — and 2025, when it sank 96.91%.
- ImmunityBio's Receivables - Other stood at $1.9 million in 2022, then gained by 6.83% to $2.0 million in 2023, then sank by 90.09% to $200000.0 in 2024, then plunged by 77.0% to $46000.0 in 2025, then plunged by 93.48% to $3000.0 in 2026.
- Business Quant data shows IBRX's Receivables - Other at $3000.0 in Q1 2026, $46000.0 in Q4 2025, and $1.7 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 10 | ImmunityBio | 8.45 Bn | 8.10 Bn | 50.94 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 27,000.00 |
| Mar 31, 2026 | 3,000.00 |
| Dec 31, 2025 | 46,000.00 |
| Sep 30, 2025 | 1.68 Mn |
| Jun 30, 2025 | 204,000.00 |
| Mar 31, 2025 | 424,000.00 |
| Dec 31, 2024 | 293,000.00 |
| Sep 30, 2024 | 729,000.00 |
| Jun 30, 2024 | 1.03 Mn |
| Mar 31, 2024 | 2.14 Mn |
| Dec 31, 2023 | 2.02 Mn |
| Sep 30, 2023 | 2.33 Mn |
| Jun 30, 2023 | 2.03 Mn |
| Mar 31, 2023 | 1.46 Mn |
| Dec 31, 2022 | 1.89 Mn |
| Sep 30, 2022 | 5.00 Mn |
| Jun 30, 2022 | 5.01 Mn |
| Mar 31, 2022 | 3.89 Mn |
| Dec 31, 2021 | 1.33 Mn |
| Sep 30, 2021 | 1.30 Mn |